NZ630367A - Methods of treatment of pediatric solid tumor - Google Patents

Methods of treatment of pediatric solid tumor

Info

Publication number
NZ630367A
NZ630367A NZ630367A NZ63036714A NZ630367A NZ 630367 A NZ630367 A NZ 630367A NZ 630367 A NZ630367 A NZ 630367A NZ 63036714 A NZ63036714 A NZ 63036714A NZ 630367 A NZ630367 A NZ 630367A
Authority
NZ
New Zealand
Prior art keywords
solid tumor
treatment
methods
pediatric solid
individual
Prior art date
Application number
NZ630367A
Other languages
English (en)
Inventor
Neil P Desai
Bouchra Benettaib
Markus Renschler
Ileana Elias
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of NZ630367A publication Critical patent/NZ630367A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
NZ630367A 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor NZ630367A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361780658P 2013-03-13 2013-03-13
US201361805817P 2013-03-27 2013-03-27
US201361829940P 2013-05-31 2013-05-31
US201361909868P 2013-11-27 2013-11-27
PCT/US2014/022541 WO2014143613A1 (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor

Publications (1)

Publication Number Publication Date
NZ630367A true NZ630367A (en) 2017-02-24

Family

ID=51537501

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ630367A NZ630367A (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor

Country Status (12)

Country Link
US (1) US20160015817A1 (enExample)
EP (1) EP2968253A4 (enExample)
JP (3) JP6387389B2 (enExample)
KR (1) KR20150126671A (enExample)
CN (1) CN105209035A (enExample)
AU (2) AU2014228386B2 (enExample)
CA (1) CA2903470A1 (enExample)
HK (1) HK1219231A1 (enExample)
IL (1) IL240987A0 (enExample)
MX (1) MX2015011783A (enExample)
NZ (1) NZ630367A (enExample)
WO (1) WO2014143613A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス, エルエルシー 肺がんを処置する方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス, エルエルシー 膀胱がんを処置する方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CN1101700C (zh) * 1997-12-05 2003-02-19 上海众联生化技术开发有限公司 多肽口服液
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
CN1261161C (zh) * 2003-11-10 2006-06-28 钱汶光 复方干扰素诱生剂口含片
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
EP2502078A1 (en) * 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
KR20130028727A (ko) * 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
CN103221042B (zh) * 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法

Also Published As

Publication number Publication date
MX2015011783A (es) 2015-12-01
JP2019163334A (ja) 2019-09-26
AU2019201357A1 (en) 2019-03-21
EP2968253A1 (en) 2016-01-20
JP2016512513A (ja) 2016-04-28
IL240987A0 (en) 2015-11-30
EP2968253A4 (en) 2016-11-02
CA2903470A1 (en) 2014-09-18
US20160015817A1 (en) 2016-01-21
HK1219231A1 (zh) 2017-03-31
AU2014228386A1 (en) 2015-09-24
JP2018062528A (ja) 2018-04-19
AU2014228386B2 (en) 2018-11-29
KR20150126671A (ko) 2015-11-12
CN105209035A (zh) 2015-12-30
JP6387389B2 (ja) 2018-09-05
WO2014143613A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
NZ719049A (en) Cancer treatment with combination of plinabulin and taxane
MX2021004828A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
NZ734971A (en) Methods of treating pancreatic cancer
SG10201810888XA (en) Compositions and methods comprising bupropion or related compounds and dextromethorphan
BR112015019064A2 (pt) métodos de tratamento de melanoma
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
PH12012502380B1 (en) Methods of treatment of pancreatic cancer
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
BR112015032758A2 (pt) nanopartículas poliméricas de docetaxel para o tratamento de câncer
PH12015502302A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2014153385A3 (en) Methods of treating metabolic disorders
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MY196979A (en) Method of treating disease by auricular anesthesia of cranial nerves
MX359686B (es) Formulaciones de nanoparticulas de polionasol líquidas y en gel.
MX2016005614A (es) Cuerpos de inclusion para el suministro transdermico de agentes terapeuticos y cosmeticos.
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2019 BY AJ PARK

Effective date: 20171212

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2020 BY COMPUTER PACKAGES INC

Effective date: 20190219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2022 BY CPA GLOBAL

Effective date: 20210128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2023 BY CPA GLOBAL

Effective date: 20220205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2024 BY CPA GLOBAL

Effective date: 20230202

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 10 MAR 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250130